Sign up
Pharma Capital

CURE Pharmaceutical joins forces with Canopy Growth in exclusive partnership

CURE Pharmaceutical Holding Corp (OTCMKTS:CURR) COO Jessica Rousset tells Proactive Investors the drug manufacturing company has signed a deal with Canopy Growth Corp (TSX:WEED, NYSE:CGC), where Canopy will have an exclusive license to CURE's patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.

Rousset says the licence agreement allows CURE to accelerate and expand the impact of its technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.

 

View full CURR profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.